The ALDH1B1 Knockout KYSE-150 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the KYSE-150 human esophageal squamous cell carcinoma line. This product provides a heterogeneous pool of cells harboring CRISPR/Cas9-mediated disruption of the ALDH1B1 gene, offering a robust loss-of-function model for studying aldehyde dehydrogenase 1 family member B1 function. The polyclonal format allows researchers to examine the collective impact of ALDH1B1 ablation without clonal selection artifacts, making it suitable for population-level analyses. As a research tool, these cells enable detailed investigation of ALDH1B1-dependent processes in a biologically relevant cancer model.
The parental KYSE-150 cell line was established from a well-differentiated human esophageal squamous cell carcinoma and is widely employed as an in vitro model for esophageal cancer research. These cells retain key features of the originating tumor, including characteristic morphology and molecular signatures, facilitating translational studies. The KYSE-150 background provides a context in which ALDH1B1 is endogenously expressed, making it an ideal host for knockout studies aimed at dissecting its role in esophageal tumorigenesis.
ALDH1B1 functions as an NAD+-dependent aldehyde dehydrogenase that catalyzes the oxidation of endogenous and exogenous aldehydes, notably converting retinaldehyde to retinoic acid. This enzymatic activity positions ALDH1B1 at a critical node in retinoic acid biosynthesis and signaling, where it transcriptionally regulates retinoic acid-responsive genes such as RAR?? and CYP26A1. Upstream, ALDH1B1 is regulated by the ??-catenin/TCF transcription complex and Notch signaling, while retinoic acid receptors (RARs) and cytokines like IL-6 further modulate its expression. The enzyme operates alongside ADH, RAR??, RXR, and CRABP in retinoic acid metabolism, and influences stemness factors including SOX2, OCT4, and NANOG. ALDH1B1 also interfaces with detoxification pathways, interacting with other ALDH isozymes and potentially ??-catenin.
In esophageal squamous cell carcinoma, ALDH1B1 contributes to cancer stem cell maintenance and chemoresistance. By driving retinoic acid signaling and detoxifying aldehydes, ALDH1B1 promotes a stemness phenotype and reduces sensitivity to chemotherapeutic agents such as cisplatin and 5-FU. Disruption of ALDH1B1 in KYSE-150 cells therefore provides a valuable model for elucidating the molecular mechanisms underlying tumor-initiating cell populations and therapy failure. This knockout model is particularly relevant for exploring the intersection of alcohol metabolism, retinoic acid signaling, and Wnt/??-catenin pathways in esophageal cancer.
The ALDH1B1 Knockout KYSE-150 Polyclonal Cells are suitable for a range of experimental applications, including cancer stem cell biology investigations, chemotherapy resistance studies, and retinoic acid signaling pathway analyses. Researchers can employ functional assays such as ALDEFLUOR activity measurement, sphere formation assays, and Western blotting for stemness markers. Transcriptomic profiling via RNA-seq and RT-qPCR can monitor downstream target gene expression, while drug sensitivity assays with cisplatin or 5-FU assess chemoresistance. Migration and invasion assays further enable phenotypic characterization. For additional information or technical support, please contact Ascent Research.
